Virpax announces agreement with the u.s. department of health and human services for the developmental extension for nes100 towards ind for acute and chronic non-cancer pain alternative

Berwyn, pa.--(business wire)--virpax pharmaceuticals, inc. (nasdaq: vrpx) (“virpax” or the “company”), a company specializing in developing pharmaceutical products for pain management, announced that it has been granted an extension of its cooperative research and development agreement with the national center for advancing translational sciences (ncats), an institute/center of the national institutes of health (nih), u.s. department of health and human services. this collaboration is for the c.
NES Ratings Summary
NES Quant Ranking